EHC Puts Pile Up as Short Interest Climbs Into Q3 Results

Encompass Health reports third-quarter results today with options traders running the most defensive positioning seen in months, even as short sellers face no meaningful friction in the borrow market.

The put/call ratio closed at 3.42 on Tuesday, well above its 20-day average of 1.23 and roughly 1.6 standard deviations from normal. That reading has held above 3.0 for five consecutive sessions, a sustained shift rather than a single-day spike. The pattern marks a sharp break from late September and early October, when the ratio sat below 0.28, meaning the market was firmly call-skewed. Short interest contributed its own signal: positions rose 16% over the past week to 3.25% of the free float, a move roughly 1.5 standard deviations above the company's typical weekly shift. The borrow market offers no reinforcement for bearish conviction, however. Availability is extremely loose at 6,000%, with around 69 million shares available against only 3.3 million borrowed, and borrowing costs are negligible at 0.33% annualised. Encompass Health gained 0.5% on Wednesday and 1.3% over the week, holding up against a peer group that fell a median of roughly 3.5%, with ENSG down 3.7% and UHS off 4.5%.

The debate around the stock centres on whether its structural growth story can absorb persistent cost pressure. The bull case rests on an inpatient rehabilitation market that remains undersupplied relative to demand from an aging patient base. The most recent quarterly result beat EBITDA consensus by 3% despite an $11.5 million headwind from supplemental data payments, and the company raised full-year EBITDA guidance by $15 million. Leverage sits at 1.9x, leaving room for bed expansion and buybacks. Bears point to staffing costs that persistently outrun reimbursement, the recurring MedPAC recommendation for a 7% cut to IRF Medicare fee-for-service rates (estimated to reduce EBITDA by around 18% if enacted), and Medicare Advantage plans tightening admissions and denial rates. The analyst community leaned constructively after the last print: several firms raised targets in August, with UBS lifting to $155 and Truist to $150, though those actions are now around 80 days old and the consensus mean of $148 sits roughly 21% above the current price of $122.

Retail attention has ticked up sharply heading into the release. Wikipedia page views for Encompass Health are running at a z-score of 2.2 against the company's own 90-day history, placing current attention well above the recent baseline. This dataset has not been measured to lead the company's reported figures, so it reflects interest rather than a signal on the quarter.

Today's print will test whether the volume and margin trajectory from Q2 has carried through a quarter complicated by staffing dynamics and managed care friction, and whether guidance for the full year holds at the raised level set three months ago.